These findings were validated using an in vivo mouse model that allowed us to inducibly silence EDI3 in HCC1954 cells by the addition of doxycycline [6], which altogether support EDI3 as a potential treatment target in ER-HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.